Determinants of thiazide induced hyponatraemia in pre-exposed elderly * a controlled experiment

• Conditions: hyponatremia; sodium deficiency; 10057166

• Registration Number: NL-OMON31283
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 13 May 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 36

Inclusion Criteria

Age 60-80 years
Previously admitted with thiazide-induced hyponatraemia
Patients must be willing and medically able to discontinue anti-hypertensive therapy six weeks before the study and for the duration of the study
Patients must be willing to be admitted for at least 8 hours and must be medically able to take the study medication (one tablet of hydrochlorothiazide 50 mg).
Patients must be willing to give informed consent.

Exclusion Criteria

Other causes for hyponatraemia (e.g. heart failure, pulmonary disease, medication associated with hyponatraemia).;- Renal dysfunction (estimated clearance <50 ml/min according to Cockroft-Gault)
- Liver cirrhosis
- Use of beta-blocking agents for coronary disease
- Heart failure
- Allergy for sulfonamide-derivatives
- Therapy resistant hypertension (BP>140/90 mmHg while using 3 or more anti-hypertensive drugs)
-stage II hypertension or higher while using 2 anti-hypertensive drugs (BP > 160/100))
-uncontrolled hypertension (BP > 180/110))

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Differences in the ADH-AQP2 ratio between patients previously admitted with<br /><br>thiazide induced hyponatremia and matched controls without previous thiazide<br /><br>induced hypoantremia. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary endpoints are differences in prostaglandin E2 and AVPR2 expression.</p><br>